Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.69, $0.25 better than the analyst estimate of $0.44. Revenue for the quarter came in at $175.69 million versus the consensus estimate of $157.3 million.

GUIDANCE:

Supernus Pharma sees FY2024 revenue of $630-650 million, versus the consensus of $619.5 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.